179686-64-7

Basic information

• Product Name: methyl N-(2-nitrobenzyl)glycinate
• Synonyms: methyl N-(2-nitrobenzyl)glycinate
• CAS NO: 179686-64-7
• Molecular Weight: 224.216
• Mol File: 179686-64-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl N-(2-nitrobenzyl)glycinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl N-(2-nitrobenzyl)glycinate(179686-64-7)
• EPA Substance Registry System: methyl N-(2-nitrobenzyl)glycinate(179686-64-7)

Safety Data

• Hazardous Substances Data: 179686-64-7(Hazardous Substances Data)

Upstream product

• 5680-79-5 glycine ethyl ester hydrochloride 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 88-72-2 1-methyl-2-nitrobenzene 
• 552-89-6 2-nitro-benzaldehyde 
• 219782-24-8 {[1-(2-Nitro-phenyl)-meth-(Z)-ylidene]-amino}-acetic acid methyl ester 

Downstream Products

• 85313-33-3 methyl N-(2-nitrobenzyl)glycinate hydrochloride 
• 1174568-18-3 methyl N-(tert-butoxycarbonyl)-N-(2-nitrobenzyl)glycinate 
• 5946-39-4 2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine 
• 1824-72-2 1,3,4,5-tetrahydro-2H-benzo[e][1,4]diazepin-2-one 
• 179686-66-9 tert-butyl 2-oxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate 
• 179686-65-8 methyl N-(2-aminobenzyl)-N-(tert-butoxycarbonyl)glycinate 
• 345201-73-2 {[2-(2-{(2-tert-butoxycarbonylamino-ethyl)-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetylamino)-benzyl]-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid methyl ester 
• 345201-78-7 {[2-(2-{(2-tert-butoxycarbonylamino-ethyl)-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetylamino)-benzyl]-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid 
• 345201-64-1 methyl N-(2-aminobenzyl)-N-(thymin-1-ylacetyl)glycinate 
• 345201-60-7 methyl N-(2-nitrobenzyl)-N-(thymin-1-ylacetyl)glycinate 

Relevant articles and documents

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and may be useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

NOVEL HETEROCYCLIC COMPOUNDS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relat